Publicaciones Similares
Biosimilars in Mexico
The regulatory body for the approval of
medicines in Mexico is the Federal Commission for Protection Against Health Risks (COFEPRIS)
Why does the Inflation Reduction Act reduce the prices of Pharmaceuticals?
The Inflation Reduction Act (IRA) is used to lower drug prices by imposing extra costs on drug manufacturers that increase their prices above the inflation rate. This forces manufacturers to keep their price increases below the inflation rate to avoid the penalty
Rare Diseases current situation in Latin America and the global drug market
The size of the global market in 2021 for the treatment of rare diseases was valued at USD 119.600 million it is expected to increase at a compound annual growth rate (CAGR) of 12.8% between 2022 and 2030.
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America
Health System in Argentina
To ensure compliance with area policies for the promotion, preservation, and recovery of the population’s health, strengthening the balance between users, providers, and financiers, in conditions of free
competition, transparency, economic efficiency, and social equity.
Biosimilars in Peru
In Peru, it is necessary to implement criteria regarding the nomenclature of biosimilar medicines and the use of identifiers that allow them to be distinguished from the innovative medicine.